JULIE ZAWISZA (Zah-Veeshah) Is the Director of CDER’s Office of Communications and has also served as FDA’s acting and Assistant Commissioner for Public Affairs.
Thomas Abrams is the Director of the Office of Prescription Drug Promotion (OPDP), Food and Drug Administration. Before becoming Director of OPDP, Mr. Abrams was Director of the Division of Drug Marketing, Advertising, and Communications.
Paul Savidge, Bristol-Myers Squibb Company, United States
Paul leads the groups that provide legal services to various BMS’ business units. The department also provides regulatory review of materials promoting BMS medicines in the US and is responsible for BMS’ interactions with FDA on advertising issues.
Dr. Garrard is Chief Safety Officer for Drug Safety Alliance, Inc. She provides leadership in strategic planning, analysis, development, implementation and measurement of all aspects of drug safety and medical services including signal management and risk evaluation and mitigation strategy.
He received his medical degree from Columbia University, and his Master's degree in clinical epidemiology from Johns Hopkins. He trained in Internal Medicine at the Hospital of the Univ of Pennsylvania, and in Neurology at Johns Hopkins. He is board certified in Internal Medicine and Neurology.
Description
Social media creates challenges and opportunities for the promotion and safety of drugs and other medical products. FDA and industry are working to optimize truthful product information and ways to gather adverse event data utilizing this resource
Learning Objectives: Describe FDA's efforts to ensure fair, balance promotion with social media Explore the effects of social media on FDA's efforts to monitor safety Discuss challenges social media present to the pharmaceutical industry's efforts to ensure fair and balanced communication about its products.